Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) and lowered the price target from $81 to $80.

July 24, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays has maintained an Equal-Weight rating on Gilead Sciences and lowered the price target from $81 to $80.
The news is directly about Gilead Sciences and is likely to impact investor sentiment. The lowering of the price target may suggest that the analyst sees less upside potential for the stock, which could influence investors' decisions. However, the maintenance of the Equal-Weight rating indicates that the analyst does not see significant downside risk either, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100